Literature DB >> 21862936

Pneumonia complicating pandemic (H1N1) 2009: risk factors, clinical features, and outcomes.

Diego Viasus1, José Ramón Paño-Pardo, Jerónimo Pachón, Melchor Riera, Francisco López-Medrano, Antoni Payeras, M Carmen Fariñas, Asunción Moreno, Jesús Rodríguez-Baño, José Antonio Oteo, Joaquín Martínez-Montauti, Julián Torre-Cisneros, Ferrán Segura, Francesc Gudiol, Jordi Carratalà.   

Abstract

We performed an observational analysis of a prospective cohort of adults hospitalized for pandemic (H1N1) 2009 at 13 Spanish hospitals, from June to November 2009, to determine the risk factors, clinical features, and outcomes of pneumonia. Of 585 patients requiring hospitalization, chest radiography was obtained in 542. A total of 234 (43.1%) patients had pneumonia, of whom 210 underwent bacterial microbiologic studies. Of these patients, 174 (82.8%) had primary viral pneumonia and 36 (17.2%) had concomitant/secondary bacterial pneumonia. Bilateral pneumonia occurred in 48.3% of patients. Streptococcus pneumoniae was the most frequent pathogen among patients with bacterial pneumonia (26 of 36 patients). None of them had received pneumococcal vaccine. Compared with patients without pneumonia, those with pneumonia more frequently had shock during hospitalization (9.8% vs. 1%; p < 0.001), required intensive care unit admission (22.6% vs. 5.8%; p < 0.001), underwent mechanical ventilation (17.9% vs. 3.2%; p < 0.001), and had longer length of hospital stay (median, 7 d vs. 5 d; p < 0.001). In-hospital mortality was higher in patients with pneumonia than in the others (5.2% vs. 0%; p < 0.001). Absence of comorbid conditions (odds ratio [OR], 2.07; 95% confidence interval [CI], 1.32-3.24) was found to be an independent risk factor for pneumonia, whereas early (≤ 48 h) oseltamivir therapy (OR, 0.29; 95% CI, 0.19-0.46) was a protective factor. In conclusion, pneumonia is a frequent complication among adults hospitalized for pandemic (H1N1) 2009 and causes significant morbidity. Mortality in pandemic (H1N1) 2009 is low, but occurs mainly in patients with pneumonia. Early oseltamivir therapy is a protective factor for this complication.

Entities:  

Mesh:

Year:  2011        PMID: 21862936     DOI: 10.1097/MD.0b013e31822e67a7

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  14 in total

1.  Elevation of creatine kinase is associated with worse outcomes in 2009 pH1N1 influenza A infection.

Authors:  Bárbara Borgatta; Marcos Pérez; J Rello; Loreto Vidaur; Leonardo Lorente; Lorenzo Socías; Juan Carlos Pozo; J C Pozo; José Garnacho-Montero; Jordi Rello
Journal:  Intensive Care Med       Date:  2012-04-18       Impact factor: 17.440

2.  Respiratory disease in Canadian First Nations and Inuit children.

Authors:  Thomas Kovesi
Journal:  Paediatr Child Health       Date:  2012-08       Impact factor: 2.253

3.  Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.

Authors:  Angela Domínguez; Jesús Castilla; Pere Godoy; Miguel Delgado-Rodríguez; Marc Saez; Núria Soldevila; Jenaro Astray; José María Mayoral; Vicente Martín; José María Quintana; Fernando González-Candelas; Juan Carlos Galán; Sonia Tamames; Ady Castro; Maretva Baricot; Olatz Garín; Tomas Pumarola
Journal:  Hum Vaccin Immunother       Date:  2013-04-01       Impact factor: 3.452

4.  Characteristics of Patients Hospitalized with 2009 H1N1 Influenza in a Tertiary Care Hospital in Southern Saudi Arabia.

Authors:  Adnan Agha; Abdulqader Alrawi; Cesar V Munayco; Mohammed S Alayed; Mohammad Al-Hakami; Hassan Korairi; Abdelhaleem Bella
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-01-06       Impact factor: 2.576

5.  Recent advances in the diagnosis and treatment of influenza pneumonia.

Authors:  Lucia Marzoratti; Hernán A Iannella; Victoria Fernández Gómez; Sandra B Figueroa
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

Review 6.  Postviral Complications: Bacterial Pneumonia.

Authors:  Jason E Prasso; Jane C Deng
Journal:  Clin Chest Med       Date:  2016-12-13       Impact factor: 2.878

7.  Community-acquired pneumonia during the first post-pandemic influenza season: a prospective, multicentre cohort study.

Authors:  Diego Viasus; Carmen Marinescu; Aroa Villoslada; Elisa Cordero; Juan Gálvez-Acebal; María C Fariñas; Irene Gracia-Ahufinger; Anabel Fernández-Navarro; Jordi Niubó; Lucia Ortega; Elena Muñez-Rubio; María P Romero-Gómez; Jordi Carratalà
Journal:  J Infect       Date:  2013-06-06       Impact factor: 6.072

Review 8.  The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09.

Authors:  Chandini Raina MacIntyre; Abrar Ahmad Chughtai; Michelle Barnes; Iman Ridda; Holly Seale; Renin Toms; Anita Heywood
Journal:  BMC Infect Dis       Date:  2018-12-07       Impact factor: 3.090

9.  Poly I:C enhances susceptibility to secondary pulmonary infections by gram-positive bacteria.

Authors:  Xiaoli Tian; Feng Xu; Wing Yi Lung; Cherise Meyerson; Amir Ali Ghaffari; Genhong Cheng; Jane C Deng
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

10.  Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis.

Authors:  Stella G Muthuri; Sudhir Venkatesan; Puja R Myles; Jo Leonardi-Bee; Wei Shen Lim; Abdullah Al Mamun; Ashish P Anovadiya; Wildo N Araújo; Eduardo Azziz-Baumgartner; Clarisa Báez; Carlos Bantar; Mazen M Barhoush; Matteo Bassetti; Bojana Beovic; Roland Bingisser; Isabelle Bonmarin; Victor H Borja-Aburto; Bin Cao; Jordi Carratala; María R Cuezzo; Justin T Denholm; Samuel R Dominguez; Pericles A D Duarte; Gal Dubnov-Raz; Marcela Echavarria; Sergio Fanella; James Fraser; Zhancheng Gao; Patrick Gérardin; Maddalena Giannella; Sophie Gubbels; Jethro Herberg; Anjarath L Higuera Iglesias; Peter H Hoeger; Matthias Hoffmann; Xiaoyun Hu; Quazi T Islam; Mirela F Jiménez; Amr Kandeel; Gerben Keijzers; Hossein Khalili; Gulam Khandaker; Marian Knight; Gabriela Kusznierz; Ilija Kuzman; Arthur M C Kwan; Idriss Lahlou Amine; Eduard Langenegger; Kamran B Lankarani; Yee-Sin Leo; Rita Linko; Pei Liu; Faris Madanat; Toshie Manabe; Elga Mayo-Montero; Allison McGeer; Ziad A Memish; Gokhan Metan; Dragan Mikić; Kristin G I Mohn; Ahmadreza Moradi; Pagbajabyn Nymadawa; Bulent Ozbay; Mehpare Ozkan; Dhruv Parekh; Mical Paul; Wolfgang Poeppl; Fernando P Polack; Barbara A Rath; Alejandro H Rodríguez; Marilda M Siqueira; Joanna Skręt-Magierło; Ewa Talarek; Julian W Tang; Antoni Torres; Selda H Törün; Dat Tran; Timothy M Uyeki; Annelies van Zwol; Wendy Vaudry; Daiva Velyvyte; Tjasa Vidmar; Paul Zarogoulidis; Jonathan S Nguyen-Van-Tam
Journal:  Influenza Other Respir Viruses       Date:  2016-02-01       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.